View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 18, 2020updated 04 Sep 2020 7:20am

China approves first anti-viral drug against coronavirus Covid-19

Anti-viral drug Favilavir has secured approval from the National Medical Products Administration of China to treat coronavirus Covid-19, according to media reports.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Anti-viral drug Favilavir has secured approval from the National Medical Products Administration of China to treat coronavirus Covid-19, according to media reports.

China Daily reported that the Taizhou government in Zhejiang province announced the approval, which marks the authorisation of the first drug against the new coronavirus.

Formerly Fapilavir, the drug was developed by Zhejiang Hisun Pharmaceutical.

Fapilavir allegedly demonstrated efficacy with minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province. The drug’s generic version received the approval.

Production of the anti-viral drug was begun on Sunday, added the news agency.

According to China’s Ministry of Science and Technology, Favilavir is one of the three drugs that showed encouraging profile for blocking the new coronavirus in early clinical trials.

The remaining two drugs are anti-malaria drug chloroquine and Gilead’s experimental drug remdesivir.


See all Coronavirus vaccines and drugs in the pipeline


Chloroquine, an existing medicine, is under assessment in more than 100 patients at over ten hospitals in Beijing and Guangdong province. Plans for an additional study in Hunan province are underway.

Meanwhile, Gilead’s drug is said to be in studies at more than ten medical institutions in Wuhan, the epicentre of the Covid-19 outbreak.

A study by the US National Institutes of Health (NIH) revealed that remdesivir could prevent the Middle East respiratory syndrome coronavirus (MERS-CoV), a type of coronavirus in monkeys, offering hope for China trials.

Earlier this month, the Wuhan Institute of Virology filed an application seeking a new patent on remdesivir.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU